Less than 10% of individuals that would benefit from weight-loss injections such as Wegovy are able to get them, caution the World Health Organization as it publishes its first guidance on the medications.
Considering in excess of 1,000,000,000 individuals worldwide now obese, it is urging increased and just access to these injectable treatments.
Based on projections, over two billion could be obese by 2030 without intervention.
"The latest guidelines recognises that excess weight is a long-term condition that can be managed with thorough and continuous treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are major barriers to universal access to the treatments that can assist patients in reducing substantial body mass, says the agency.
Weight-Loss Drug Supply Crisis
Despite the present most favorable case, the manufacturing of GLP-1 therapies might only reach around 100 million people – fewer than 10% of the global need, as stated by the WHO.
The advice encourages countries and companies to widen availability, via strategies such as licensing agreements.
A patent on the active ingredient – the core ingredient of a leading brand – is scheduled to end in a number of countries in 2026.
The Way Obesity Drugs Function
The injections mimick a body's own hormone to reduce digestion speed, reduce hunger and boost feelings of fullness so people consume fewer calories.
People typically start to lose weight within a few weeks of starting on the once-weekly jabs.
Studies suggests users may see weight return after a year of discontinuing the treatment, when their usual appetite resume.
Being carrying excess weight elevates your likelihood for developing medical conditions, including type 2 diabetes, heart disease, brain attack, and some cancers.
Excess weight affects individuals in countries worldwide and was responsible for over three and a half million deaths worldwide in 2024, per the WHO.
